chapter 15 CNS Flashcards
use of anorexiants
- prescription weight-loss drugs are used for pt. BMI >30 or BMI>27 with DM, HTN, dyslipidemia
- serious side effects-cardiac, pulmonary ADRs-possibly fatal
- avoid in patients with cardiac hx, drug/ETOH abuse
- difficult to monitor pts with diabetes-increased glucose uptake from skeletal muscles
Anorexiants
-for short term use only
-related to amphetamines-suppresses appetite
-Diethylpropion (Tenuate, Tenuate Dospan Cat-IV)
-Orlistat (Xenical, Alli OTC)-only non-stimulant-lipase inhibitor; preg. cat. X
-phentermine (Adepex-P)
-Sibutramine (meridia)
-
pharmacodynamics of anorexiants
- release of norepi/dopamine from storage sites in lateral hypothalmic feeding center
- decreases appetite
pharmacokinetics of anorexiants
- lipid soluble with wide distribution
- crosses BBB
- metabolized by liver and excreted by kidneys
- duration of action 4-6 yrs
pharmacotherapeutics of anorexiants
- high risk of dependence (avoid pts with ETOH/drug dependence)
- avoid pt who abuse cocaine/methamphetamines-d/t additional adrenergic stimulation
ADRs for anorexiants
- overstimulation of CNS-agitation, insomnia, dizziness, HTN, etc
- may cause withdrawal symptoms if suddenly stop
- increased glucose uptake from skeletal muscles
drug interactions for anorexiants
- off label in combo with SSRI: “Phen-Pro” (prozac and phentermine)
- with serotonergic meds-blks seratonin production and causes seratonin syndrome (severe muscle rigidity can lead to death)
- cyproheptadine anecdote
- MAO inhibitors could lead to HTN crisis
- lithium toxicity
- cautious with: adrenergic blks, insulin sulfonylureas, phenothiazines
- Orlistat decreases level of levothyroxine and increases warfarin
ADHD
- persistent hyperactivity and impulsivity
- tx: behavior therapy and medication therapy (stimulant and non-stimulant options; used to help with alertness, focus, attention
- most common drug: MPH (methylphenidate)
- all stimulants are controlled substance
MPH
MAO: blks dopamine reuptake
M: de-esterification to inactive metabolite
AE: insomnia, decreased appetite, weight loss
Rare AE: tics, visual hallucinations
Caution: hx psychosis, mania, drug addiction
DI: carbamazepine, clonidine, warfarin, phenobarb, phenytoin, TCAs
-short and long acting available
* concerta with pt with esophageal motility issues-may increase risk of obstruction
Adderall and Vyvanse
- amphitamines for ADHD
- ? vyvanse less abuse potential
- ADRs: decreased appetite, insomnia, abd pn
- risk of sudden cardiac death
non-stimulant meds for ADHD
- atomoxetine (Strattera)
- MAO: inhibitor of norepi reuptake
- metabolized in CYP2D6
- ADRs: dyspepsia, decreased appetite, wt. loss, no tics
- can cause severe liver injuries, suicidal ideation
adjunct meds for ADHD
- buproprion
- clonidine: cautious for sedation
- TCA: monitor EKG first
- guafacine: less sedation longer action
- modanifil-not recommended-hallucinations, Stevens Johnson syndrome
parkinsons disease
- loss of neurons in substantia nigra
- presence of Lewy bodies
- loss of dopamine 1 and 2-leading to increased cholinergic activity
- symptoms: bradykinesia, resting tremor, postural instability
- progression: depression and psychosis
dopaminergics/dopamine agonist
- choice of tx for parkinson’s
- attempt to restore functional balance of dopamine and acetylcholine-both responsible for smooth movements and balance
- either by increasing synthesis, increasing receptors, release from storage, or inactivating MAO leading to more amounts available
i. e.: amantadine, bromocriptine, levodopa (carbidopa-levodopa), pramipexole, ropinirole
- either by increasing synthesis, increasing receptors, release from storage, or inactivating MAO leading to more amounts available
- many drug intereactions
- can not stop abruptly
- cautious with patients with impulse-control disorders (pathologic gambling, binge eating, hypersexuality, excessive shopping etc)
- “sleep attacks”-suddenly fall asleep
- confusion and toxic psychosis
cabidopa/levodopa
-combination enhances transmission of levodopa across BBB
-levodopa precursor to dopamine
-carbidopa: increases CNS penetration, prevents peripheral dopamine metabolism
ADRs: n/v, arrhythmias, postural hypotension, nightmares
-always given in combination
-absorption: levodopa protein bound, food delays gastric emptying
-controversial when to start tx, enhances neuron degradation, builds dose tolerance
catechol-O-methyltranserase inhibitor (COMT)
- blocks degradation of levodopa
- entacopone-may have sleep attacks
- tolcapone-hepatotoxicity-monitor LFTs
- decreases levodopa requirements
- adrs: dyskinesias, n/d, discolored urine
ergot derivatives for parkinsons
- bromocriptine: limited efficacy, risk of pulmonary fibrosis
- pergolide: removed from market d/t cardiac valve regurg
MAO-B inhibitors for parkinsons
- selegiline, rasagiline
- inhibits catabolism and reuptake of dopamine
- can be mono or adjunctive therapy
- caution with SSRIs, meperidine, tramadol
- lower dose than for depression
- adrs: nausea, orthostatic hypotension, may enhance adrs of levodopa
anticholinergics for parkinsons
- trihexyphenidyl, benztropine, ethopropazine
- limited role d/t ADRs
- used for tremors and drooling
drugs associated with seizure activity
- antidepressants: SSRIs, TCA, buproprion
- quinolones
- high dose pcn
- cabepenems
- theophylline
- tramadol
- cyclosporins
- ETOH, drug, benzo withdrawal
anticonvulsants
- seizures are result of abnormal discharge off neurons-anything that disrupts stability of neurons may cause
- can be used for tx of mood disorders
- precipitating factors: stress, high intake of caffeine, sleep deprivation, infection, sensory stimuli, hormonal change, metabolic disorders
- classes: hydantoins, iminostilbenes, succinimides
- main actions: stimulating influx of chloride ions-assoc. with GABA neurotransmitter
- delaying influx of Na+
- delaying influx of Ca+ - may cause suicide ideation and depression
- consider levels-toxicity and compliance
- there are many drug interactions
hydantoins
- phenytoin-most commonly used, ethotoin, fosphenytoin
- inhibit and stabilize electrical discharge in motor cortex of brain
- first line tx for tonic-clonic and partial complex seizures
phenytoin (Dilantin)
- stabilize Na+ channels
- dose: loading: 15-20mg/kg, maintenance: 4-7mg/kg/day
- metabolized: non-linear kinetics enzyme inducer
- many drug interactions
- caution: hypothyroidism, carbohydrate intolerance, peripheral neuropathy
- toxicity: n/v, tachycardia,
- adrs: nystagmus, ataxia, drowsiness, cognitive impairment (dose related)
- gingival hyperplasia, hirsutism, acne, rash, coarse facial features, osteomalacia, vit D and folic acid deficiency
levetiracetam (Keppra)
- for epilepsy and partial seizures/mono or adjunct therapy
- prevents epileptiform burst firing
- propagation of seizure activity
- dose 500mg BID (max of 3g/day)-adjust for renal impairment
- not largely metabolized-non-hepatic hydrolysis
- adrs: sedation, fatigue, agitation, lethargy
- levels: 12-46 mcg/ml
- pregnancy C
iminostilbenes
- used to treat epilepsy, bipolar affective disorder, aggressive behavior, neuralgias
- carbamazepine (tegretol)
carbemazepine (Tegretol)
- structurally related to TCAs
- inhibits Na+ channels-to prevent seizure activity
- metabolized by autoinduction-to induce its own metabolism; CYP3A4, 1A2 inducer
- half life 25-65 hrs decreases to 12-16 hours
adrs: black box warning blood dyscrasias, rash, ostomalacia, hepatotoxicity, lupus, diplopia, nystagmus
levels: 4-12 mcg/ml
- half life 25-65 hrs decreases to 12-16 hours
oxcarbazepine
- mono or adjunct therapy for partial seizures
- Na+ channel blker
- metabolized in liver: 3A4 inducers, 2C19 inhibitors
- half life 9 hrs
- adrs: hyponatremiz, rash, less blood dyscrasias than cabazepine
levels: 3-35 mcg/ml - pregnancy cat C
phenobarbital
- for epilepsy low doses to not have dependence or tolerance
- can be used for tonic-clonic seizures
- increases aminobutyric acid and chloride influx-causing decrease activity and induce sleep
- CYP enzyme inducer; half life 80-100 hrs
- level 15-40 mcg/ml
- drug interactions: other benzos
- adrs: faitugue, depression, cognitive impairment, hyperactivity (pediatrics)
- preg. class D
- enhanced excretion: urinary alkaline, diuretics
valproic acid
- used for primary generalized, absent seizures in adults, myclonic, atonic
- potentiates GABA, membrane stabilization, K+ channels
- 10-15 mg/kg/day TID (ER 15% higher)
- metabolized in liver-1 is hepatotoxic, 10 metabolites, CYP 2C9, 2C19
- many drug interactions including antacids
- enzyme inducer
adrs: GI, derm, wt gain, ataxia, hepatotoxicity, thombocytopenia - preg. class D
levels: 40-100 mcg/ml
gabapentin
- inhibits Ca+ channels, enhances GABA
- 2nd line for partial seizures
- dose 300-400 mg; titrate, renal dosing
- can be used for neuropathic pn
adrs: somnolence, sedation - preg. class C
pregabalin
- GABA analog; potency>gabapentin
- used for fibromylagia, postherpetic neuralgia
- dose: 50 mg TID (max 600 mg/day), renal dose
adrs: wt. gain, dizziness, somnolent - CNS depressant
- avoid in CHF patients
- controlled substance
succinimides
- treatment of absence seizures in children/adults
- decreases nerve impulses/transmission in motor cortex leading to higher seizure threshold
- ethosuximide, mehsuximide
ethosuximide
- inhibits Ca+ channels
- dose: 250 mg BID (max 1.5 g/day)
- used for absence seizures
- level: 40-100 mcg/ml
- metabolized in liver, hepatic hydroxylization, 3A4 involvement
- excretion through renal and feces
- half life 60 hrs
- drug interactions with 3A4 meds
adrs: GI upset, wt loss, CNS depression, derm, abnormal LFTs, blood dyscrasias - preg. class c
adjunctive therapies for seizures
- topiramate and zonisamide
- topiramate-blocks Na+channels, potentiates GABA, blks glutamate, carbonic anhydrase inhibitor; can be used for migraines
- zonisamide: suppresses focus of seizures via Na+ and Ca+ channels; avoid sulfa allergy,
adrs: nephrolithiasis
migraines
3 categories: migraine with aura (classic), without aura (common), complicated migraine-treated by drugs the same
- patho: vascular theory: aura created by vasoconstriction of intracranial vessels and vasodilation of affected vessels-disproven
- sertonin: changes cause release of vasoactive neurotransmitter, causes inflammatory response, excitory serotonin receptors activated
- acute abortive therapy v. prophylactic therapy